BR0315704A - Derivados do propargil - trifluorometoxi - amino - benzotiazol - Google Patents
Derivados do propargil - trifluorometoxi - amino - benzotiazolInfo
- Publication number
- BR0315704A BR0315704A BR0315704-0A BR0315704A BR0315704A BR 0315704 A BR0315704 A BR 0315704A BR 0315704 A BR0315704 A BR 0315704A BR 0315704 A BR0315704 A BR 0315704A
- Authority
- BR
- Brazil
- Prior art keywords
- present
- amino
- alkyl
- integer
- propargyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
"DERIVADOS DO PROPARGIL - TRIFLUOROMETOXI - AMINO - BENZOTIAZOL". A invenção em questão fornece compostos possuindo a estrutura (I) : onde R~ 1~ está presente ou ausente, e quando presente é H, alquila C~ 1~ - C~ 6~, alquinila C~ 1~ - C~ 6~, (CH~ 2~)~ y~ S (CH~ 2~)~ x~ CH~ 3~, aminoalquila C~ 1~ - C~ 6~, hidroxialquila C~ 1~ - C~ 6~ ou (CH~ 2~)~ n~ C (=O) (C~ 6~H~ 4~) (CH~ 2~) R~ 2~; R~ 2~ é H ou alquila C~ 1~ - C~ 4~; R~ 3~ H ou alquila C~ 1~ - C~ 4~; R~ 4~ está presente ou ausente, e quando presente é H, alquila C~ 1~ - C~ 6~, alquinila C~ 1~ - C~ 6~, (CH~ 2~)~ y~ S (CH~ 2~)~ x~ CH~ 3~, aminoalquila C~ 1~ - C~ 6~, hidroxialquila C~ 1~ - C~ 6~ ou (CH~ 2~)~ n~ C (=O) (C~ 6~ H~ 4~) (CH~ 2~) R~ 2~; onde n é um número inteiro de 1 -6; onde x é 0 ou um número inteiro de 1 - 5 e y é um número inteiro de 1 - 5, tal que x + y < 6, no mínimo um de R~ 1~ ou R~ 4~ está presente; a linha pontilhada representa uma ligação entre um dos átomos de nitrogênio e o átomo de carbono interposto; e qualquer composto possui carga quando ambos R~ 1~ e R~ 4~ estão presentes, ou qualquer seu enanciómero específico ou qualquer seu sal farmaceuticamente aceitável, e um método para tratamento de um distúrbio neurológico ou esclerose múltipla pela administração de uma quantidade terapeuticamente eficaz de qualquer um dos compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30154002A | 2002-11-21 | 2002-11-21 | |
| PCT/US2003/037592 WO2004047756A2 (en) | 2002-11-21 | 2003-11-20 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0315704A true BR0315704A (pt) | 2005-09-06 |
Family
ID=32392394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0315704-0A BR0315704A (pt) | 2002-11-21 | 2003-11-20 | Derivados do propargil - trifluorometoxi - amino - benzotiazol |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1569641A2 (pt) |
| JP (1) | JP2006507350A (pt) |
| KR (1) | KR20050083951A (pt) |
| CN (1) | CN1741802A (pt) |
| AU (1) | AU2003295898A1 (pt) |
| BR (1) | BR0315704A (pt) |
| CA (1) | CA2507414A1 (pt) |
| IS (1) | IS7906A (pt) |
| MX (1) | MXPA05005414A (pt) |
| NO (1) | NO20052979L (pt) |
| RU (1) | RU2005119307A (pt) |
| WO (1) | WO2004047756A2 (pt) |
| ZA (1) | ZA200504988B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012050971A2 (en) * | 2010-09-29 | 2012-04-19 | Teva Pharmaceutical Industries Ltd. | Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use |
| CN103340859A (zh) * | 2013-06-04 | 2013-10-09 | 中国科学院昆明动物研究所 | 侧脑室mpp+给药建立非人灵长类帕金森病动物模型的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59112978A (ja) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | プロピニルアミノチアゾ−ル誘導体 |
-
2003
- 2003-11-20 CA CA002507414A patent/CA2507414A1/en not_active Abandoned
- 2003-11-20 RU RU2005119307/04A patent/RU2005119307A/ru not_active Application Discontinuation
- 2003-11-20 MX MXPA05005414A patent/MXPA05005414A/es not_active Application Discontinuation
- 2003-11-20 EP EP03787112A patent/EP1569641A2/en not_active Withdrawn
- 2003-11-20 KR KR1020057009216A patent/KR20050083951A/ko not_active Application Discontinuation
- 2003-11-20 JP JP2004555702A patent/JP2006507350A/ja active Pending
- 2003-11-20 BR BR0315704-0A patent/BR0315704A/pt not_active Application Discontinuation
- 2003-11-20 WO PCT/US2003/037592 patent/WO2004047756A2/en not_active Application Discontinuation
- 2003-11-20 CN CNA2003801090823A patent/CN1741802A/zh active Pending
- 2003-11-20 ZA ZA200504988A patent/ZA200504988B/en unknown
- 2003-11-20 AU AU2003295898A patent/AU2003295898A1/en not_active Abandoned
-
2005
- 2005-06-17 NO NO20052979A patent/NO20052979L/no not_active Application Discontinuation
- 2005-06-22 IS IS7906A patent/IS7906A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1741802A (zh) | 2006-03-01 |
| EP1569641A2 (en) | 2005-09-07 |
| RU2005119307A (ru) | 2006-01-27 |
| AU2003295898A1 (en) | 2004-06-18 |
| JP2006507350A (ja) | 2006-03-02 |
| WO2004047756A2 (en) | 2004-06-10 |
| MXPA05005414A (es) | 2006-05-25 |
| WO2004047756A3 (en) | 2004-07-08 |
| NO20052979L (no) | 2005-08-19 |
| NO20052979D0 (no) | 2005-06-17 |
| IS7906A (is) | 2005-06-22 |
| CA2507414A1 (en) | 2004-06-10 |
| KR20050083951A (ko) | 2005-08-26 |
| ZA200504988B (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| HUP0103366A2 (hu) | Citokin inhibítorként használható amidszármazékok | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| ATE440603T1 (de) | 8-hydroxychinolinderivate | |
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| KR950704228A (ko) | 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors) | |
| BR0012697A (pt) | Inibidores da diferenciação de th2 | |
| JP2009541489A5 (pt) | ||
| BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
| EA200000385A1 (ru) | Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4) | |
| BRPI0515628A (pt) | composto de 2-morfolina-4-pirimidona | |
| HK1080456A1 (en) | N-substituted hydromorphones and the use thereof | |
| MY109846A (en) | Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them | |
| HK1091481A1 (en) | Therapeutic agents useful for treating pain | |
| CY1109245T1 (el) | Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα | |
| WO2005030766A8 (en) | Phenyl - carboxamide compounds useful for treating pain | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| PT1250340E (pt) | Metodos e compostos para inibicao de mrp1 | |
| EP0779074A4 (en) | PROTECTIVE AGENT FOR ORGAN OR FABRIC | |
| PT838223E (pt) | Inibidor do edema cerebral | |
| BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b | |
| BR0315704A (pt) | Derivados do propargil - trifluorometoxi - amino - benzotiazol | |
| WO2004054565A8 (en) | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders | |
| DE69812028D1 (de) | Creatine Derivate für Asthma | |
| NO20012443D0 (no) | Benzoksazolderivater og legemidler inneholdende disse som aktiv bestanddel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |